Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Posts Slight Rise in Q2 Revenues, Modest Profit

NEW YORK (GenomeWeb News) — Transgenomic yesterday said first-quarter revenues inched up 1.5 percent as R&D spending increased 7 percent and the company turned last year’s loss to a modest profit.     
 
Total receipts for the three months ended June 31 rose to $6.3 million from $6.2 million year over year.
 
Transgenomic CEO Craig Tuttle said in a statement that the company saw “substantial improvement” over the previous quarter, adding that molecular diagnostics sales grew by over $200,000 compared with the first quarter of 2006.
 
Instruments and consumables sales “met internal projections,” Tuttle said, but the company’s pharmaceutical research services segment fell short of expectations due to “timing issues with receiving samples from some of our key pharmaceutical partners.”
 
R&D spending dipped to $492,000 from $531,000 year over year.
 
Transgenomic said its net income was $226,000, compared to a loss of $383,000 in the year-ago period. The most recent quarter included a $900,000 gain from the sale of securities and $600,000 in restructuring charges.
 
Tuttle said the company expects to realize “the full impact” of ongoing consolidations and other cost-reduction efforts by the fourth quarter of 2007.
 
Tuttle also predicted “strong financial performance in our traditional mutation discovery tools business and substantial growth in our diagnostics laboratory business and pharmaceutical research services business.”
 
Transgenomic said it had around $7.9 million in cash and cash equivalents as of June 30.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.